**Supplementary Material**

Supplementary Table S2. Association of inflammatory scores with outcome in stable HFrEF and treatment naïve cancer patients.

**2A. HFrEF (n=443)**

| Score | Adj.HR\(^{a}\) | p-value | Adj.HR\(^{b}\) | p-value | Adj.HR\(^{c}\) | p-value | Adj.HR\(^{d}\) | p-value |
|-------|----------------|---------|----------------|---------|----------------|---------|----------------|---------|
| NLR   | 1.03 (0.95 – 1.11) | 0.514 | 1.04 (0.98-1.11) | 0.166 | 1.04 (0.98 – 1.03) | 0.177 | 1.05 (0.99-1.12) | 0.088 |
| MLR   | 1.21 (1.11 – 1.32) | 0.075 | 1.08 (1.01-1.15) | 0.017 | 1.07 (1.01 – 1.15) | 0.033 | 1.10 (1.03-1.17) | 0.006 |
| PLR   | 1.07 (0.99 – 1.15) | 0.306 | 1.31 (1.04-1.66) | 0.024 | 1.31 (1.05 – 1.62) | 0.015 | 1.26 (1.00-1.004) | 0.047 |
| PNI   | 0.89 (0.80 – 0.98) | 0.017 | 0.83 (0.75-0.91) | <0.001 | 0.82 (0.73 – 0.91) | <0.001 | 0.84 (0.76-0.92) | <0.001 |

**2B. Cancer (n=375)**

| Score | Adj.HR\(^{c}\) | p-value | Adj.HR\(^{d}\) | p-value |
|-------|----------------|---------|----------------|---------|
| NLR   | 1.03 (1.01 – 1.05) | 0.007 | 1.03 (1.00 – 1.05) | 0.025 |
| MLR   | 1.04 (1.01 – 1.07) | 0.004 | 1.05 (1.01 – 1.08) | 0.005 |
| PLR   | 1.06 (1.03 – 1.12) | 0.013 | 1.05 (0.99 – 1.11) | 0.058 |
| PNI   | 0.94 (0.89 – 0.99) | 0.024 | 0.94 (0.89 – 0.99) | 0.030 |

a) NT-proBNP  
b) NYHA  
c) Physical status confounder model: Sex, age, BMI  
d) Laboratory confounder model: creatinine, LDH, gamma-GT  
e) Tumor stage (n=348; solid tumors only)